
Jul 16, 2026
Juno Bio has secured $3.8 million in funding and opened its first dedicated sequencing lab in Oakland, California, advancing clinically actionable vaginal microbiome testing. With over 20,000 tests sold and one of the largest vaginal microbiome data repositories in existence, the UK-founded startup is scaling a platform that aims to fix a diagnostic system where 67.5% of patients were previously misdiagnosed.
Women's Health
Biotech
Startups

Jul 16, 2026
Headlines about billion-dollar AI seed rounds are reshaping how founders and investors think about early-stage capital. But data from Bison Ventures tells a more sobering story: mega first rounds have a poor track record of delivering venture-scale returns, and the real AI winners started small.
Venture Capital
AI
Startups

Jul 15, 2026
Miles Wang, a researcher at OpenAI, is in early talks to spin out a new AI-powered drug discovery startup at a reported $2 billion valuation. The discussions signal continued investor appetite for applying frontier AI to life sciences. If closed, the deal would be one of the largest seed-stage bets in the biotech-AI crossover space.
AI
Biotech
Startups

Jul 12, 2026
Three years after launching Yosemite, Reed Jobs is all-in on biotech and AI. His firm has grown to 17 people, patent cliffs are opening new drug opportunities, and AI has become central to how Yosemite operates.
AI
biotech
drug discovery

Jul 3, 2026
Anthropic unveiled Claude Science, an AI workbench designed to unify fragmented scientific tools and datasets for researchers. But the company didn't stop there — it also announced plans to develop its own pharmaceutical drugs using AI.
Anthropic
Claude
AI for Science

Jul 2, 2026
U.S. startups closed a wave of major funding rounds during a shortened holiday week, led by a $1.75B strategic investment in energy infrastructure firm Joulent. AI infrastructure, compliance tech, and biotech also featured prominently across the top 10 deals.
Funding Rounds
AI
Energy